Research programme: antiparasitics - Helix BioMedix
Latest Information Update: 17 Oct 2008
At a glance
- Originator Helix BioMedix
- Class Peptides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Leishmaniasis
Most Recent Events
- 24 Jan 2007 Preclinical trials in Leishmaniasis in USA (unspecified route)